RETRACTED ARTICLE: Long-term follow-up after sleeve gastrectomy versus Roux-en-Y gastric bypass versus one-anastomosis gastric bypass: a prospective randomized comparative study of weight loss and remission of comorbidities

Jun 27, 2018Surgical endoscopy

Long-term weight loss and health improvements after three types of stomach surgery: sleeve gastrectomy, Roux-en-Y, and one-anastomosis gastric bypass

AI simplified

GLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗

Abstract

600 patients were included in the study, with OAGB achieving significantly greater excess BMI loss than RYGB and SG at 1, 2, and 5 years (p < 0.001).

At 5 years, OAGB leads to significantly higher remission rates of type 2 diabetes (p = 0.027), hypertension (p = 0.006), and dyslipidemia (p < 0.001) compared to RYGB and SG.
RYGB did not show significant superiority over SG in the remission of type 2 diabetes and hypertension, but it achieved greater rates of dyslipidemia remission (p < 0.001).
Follow-up rates at 5 years were 91% for SG, 92% for RYGB, and 90% for OAGB.
There were no significant differences in weight loss between SG and RYGB at 1, 2, and 5 years.

AI simplified

BACKGROUND: One-Anastomosis Gastric Bypass (OAGB) has exponentially increased in the last decade, as it is associated with very low complications, mortality, readmissions and reoperations rates, and shows excellent short- and long-term benefits of weight loss and resolution of comorbidities. The aim of this study was to compare the effect of SG, RYGB, and OAGB, on short- and long-term weight loss and comorbidities resolution.

METHODS: A prospective randomized clinical study of all morbidly obese patients undergoing SG, RYGB, and OAGB, as primary bariatric procedures, was performed. Patients were randomly assigned into 3 groups: those patients undergoing SG, those ones undergoing RYGB and those ones undergoing OAGB. BMI, excess BMI loss (EBMIL) and remission of type 2 diabetes (T2DM), hypertension (HT), and dyslipidemia (DL) were assessed.

RESULTS: 600 patients were included in the study, 200 in each group. Follow-up rate at 5 years postoperatively was 91% in SG group, 92% in RYGB, and 90% in OAGB. OAGB achieves significantly greater EBMIL than RYGB and SG at 1, 2, and 5 years (p < 0.001, respectively). At 5 years, OAGB achieves significantly greater remission of T2DM (p = 0.027), HT (p = 0.006), and DL (p < 0.001) than RYGB and SG. RYGB did not show significant superiority than SG in short- and long-term remission of T2DM and HT, but achieves greater remission of DL (p < 0.001).

CONCLUSION: OAGB achieves superior mid- and long-term weight loss than RYGB and SG. There are no significant differences in weight loss between SG and RYGB at 1, 2, and 5 years. OAGB achieves better short- and long-term resolution rates of DM, HT, and DL than SG and RYGB. RYGB and SG obtain similar T2DM and HT remissions, but RYGB reaches significantly greater rates of DL remission. ClinicalTrials.gov Identifier: NCT03467646.

Full Text

Full text is available at the source.

View full text (HTML) ↗View full text (PDF) ↗

RETRACTED ARTICLE: Long-term follow-up after sleeve gastrectomy versus Roux-en-Y gastric bypass versus one-anastomosis gastric bypass: a prospective randomized comparative study of weight loss and remission of comorbidities

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief